Cargando…

Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening

BACKGROUND: The taxane cabazitaxel (CBZ) is a promising treatment for docetaxel-resistant castration-resistant prostate cancer (CRPC). However, the survival benefit with CBZ for patients with CRPC is limited. This study used screening tests for candidate drugs targeting CBZ-resistant-related gene ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hongo, Hiroshi, Kosaka, Takeo, Suzuki, Yoko, Oya, Mototsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023558/ https://www.ncbi.nlm.nih.gov/pubmed/34593983 http://dx.doi.org/10.1038/s41391-021-00426-0

Ejemplares similares

Analysis of cabazitaxel‐resistant mechanism in human castration‐resistant prostate cancer
por: Hongo, Hiroshi, et al.
Publicado: (2018)

Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer
por: Watanabe, Keitaro, et al.
Publicado: (2021)

Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2017)

Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report
por: Yanai, Yoshinori, et al.
Publicado: (2019)

No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2018)

Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report
por: Kosaka, Takeo, et al.
Publicado: (2019)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Cranial nerve palsy caused by metastasis to the skull base in patients with castration‐resistant prostate cancer: Three case reports
por: Yasumizu, Yota, et al.
Publicado: (2021)

PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer
por: Yasumizu, Yota, et al.
Publicado: (2018)

Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations
por: Kamisawa, Ken, et al.
Publicado: (2022)

Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan
por: Kosaka, Takeo, et al.
Publicado: (2019)

Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel
por: Kosaka, Takeo, et al.
Publicado: (2018)

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
por: Komori, Takahiro, et al.
Publicado: (2022)

A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report
por: Iwasawa, Tomohiro, et al.
Publicado: (2022)

Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer
por: Yamamoto, Teppei, et al.
Publicado: (2020)

Complete Response to Bicalutamide Withdrawal Prolonged for Almost 2 Years in Patients With Metastatic Prostate Cancer()
por: Hongo, Hiroshi, et al.
Publicado: (2014)

Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity
por: Kosaka, Takeo, et al.
Publicado: (2013)

Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
por: Baba, Yuto, et al.
Publicado: (2022)

Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2011)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
por: Colbourn, Donald
Publicado: (2012)

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
por: Mofid, Bahram, et al.
Publicado: (2015)

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Belderbos, Bodine P.S., et al.
Publicado: (2017)

The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Buonerba, Carlo, et al.
Publicado: (2017)

Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report
por: Hongo, Hiroshi, et al.
Publicado: (2020)

Pulmonary metastasis secondary to abiraterone‐resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case
por: Izawa, Mizuki, et al.
Publicado: (2020)

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
por: Paller, Channing J, et al.
Publicado: (2011)

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
por: Patel, Sheel A, et al.
Publicado: (2017)

Benefit of cabazitaxel in previously treated metastatic castration-resistant prostate cancer; CARD trial
por: Mishra, Ankit
Publicado: (2020)

The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation
por: Hongo, Hiroshi, et al.
Publicado: (2022)

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre
por: Noronha, Vanita, et al.
Publicado: (2016)

Brachytherapy seeds as a nidus for urethral stone formation: A case report
por: Kamisawa, Ken, et al.
Publicado: (2019)

Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer
por: Takayama, Ken-ichi, et al.
Publicado: (2021)

Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects
por: Abidi, Afroz
Publicado: (2013)

Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel
por: de Kruijff, Ingeborg E., et al.
Publicado: (2019)

Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review
por: Masuda, Tsukasa, et al.
Publicado: (2022)

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
por: Zhang, Peng-Fei, et al.
Publicado: (2021)

Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Uemura, Koichi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rrnq0ivktrug4veq2n133ad27d